HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc....

Hullo Announces Major Upgrade to Its AI Matchmaking System, Backed by Participation in Nvidia Inception, AWS Activate, and Google for Startups

Hullo Announces Major Upgrade to Its AI Matchmaking System, Backed by Participation in Nvidia Inception, AWS Activate, and Google for Startups

The upgraded platform delivers a smarter AI Matchmaking system that reduces swipe fatigue and improves meaningful connections worldwide. HO CHI MINH CITY, Vietnam, Dec. 11, 2025 /PRNewswire/ -- Hullo Dating Co., Ltd today announced a major upgrade...

Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis

Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis

SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

STRADVISION Announces Next Phase of Cloud-Driven Innovation in Collaboration with AWS

STRADVISION Announces Next Phase of Cloud-Driven Innovation in Collaboration with AWS

- Head of Data Innovation Center presents STRADVISION's next roadmap at AWS re:Invent SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- STRADVISION, a global leader in AI-based vision perception technology for vehicles, today announced its...

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety...

Autocrypt Announces Product Release of Post-Quantum PKI Product, Pioneering PQC-enabled Solutions for Automotive OEMs

Autocrypt Announces Product Release of Post-Quantum PKI Product, Pioneering PQC-enabled Solutions for Automotive OEMs

SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Leading automotive cybersecurity solutions provider AUTOCRYPT announced on December 8, 2025, the launch of "AutoCrypt PKI-Vehicles," a new next-generation Public Key Infrastructure (PKI) solution...

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product...

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its...

TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact

TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact

Through this annual program, TraceLink champions global health equity, community resilience, and shared purpose Summary TraceLink announced the eight global nonprofit recipients of its 2025 corporate grant program, supporting organizations in the...

  • 1
  • ...
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • ...
  • 27
  • menu
    menu